Apomorphine revived: fortified, prolonged, and improved therapeutical effect.
An historical review is presented of the evolution of the clinical apomorphine treatment. Some of the results from the last 10 years of psychopharmacological research have led us to the hypothesis that there exists a close relationship between abstinence and craving symptoms in drug and alcohol addicts, and that anxiety, depression, and tremor symptoms in Parkinsonism (and dementia senilis), are due to disturbances of the same, mainly dopaminergic, pathways in the CNS. In such cases, by means of effective preparations for oral use, we have utilized the synergistic effect of small amounts of apomorphine, L-dopa, and decarboxylase inhibitor with considerable therapeutic effect.
D000368:Aged; D000437:Alcoholism / Q000188:drug therapy*; D001058:Apomorphine / Q000008:administration & dosage / Q000266:history / Q000627:therapeutic use*; D001545:Benserazide / Q000627:therapeutic use; D002214:Capsules; D004338:Drug Combinations; D049671:History, 18th Century; D049673:History, 20th Century; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D019966:Substance-Related Disorders / Q000188:drug therapy*; D013607:Tablets
D002214:Capsules; D004338:Drug Combinations; D013607:Tablets; D007980:Levodopa; D001545:Benserazide; D001058:Apomorphine